U.S. Capital Wealth Advisors LLC Has $4.83 Million Stake in Amgen Inc. (NASDAQ:AMGN)

U.S. Capital Wealth Advisors LLC lowered its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 18.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,765 shares of the medical research company’s stock after selling 3,684 shares during the quarter. U.S. Capital Wealth Advisors LLC’s holdings in Amgen were worth $4,829,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. OFI Invest Asset Management bought a new position in shares of Amgen in the third quarter valued at $26,000. Briaud Financial Planning Inc acquired a new stake in shares of Amgen in the third quarter valued at approximately $26,000. BOK Financial Private Wealth Inc. bought a new position in shares of Amgen during the 4th quarter worth approximately $29,000. Providence Capital Advisors LLC bought a new stake in Amgen in the 3rd quarter valued at $30,000. Finally, Planned Solutions Inc. acquired a new stake in Amgen during the 4th quarter valued at $30,000. Institutional investors own 76.50% of the company’s stock.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 2,117 shares of the company’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $313.09, for a total transaction of $662,811.53. Following the sale, the senior vice president now owns 9,883 shares of the company’s stock, valued at $3,094,268.47. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.46% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Raymond James initiated coverage on shares of Amgen in a research report on Thursday, March 28th. They issued a “market perform” rating on the stock. UBS Group upped their target price on Amgen from $284.00 to $307.00 and gave the company a “neutral” rating in a research report on Friday. William Blair raised Amgen from a “market perform” rating to an “outperform” rating in a report on Friday. BMO Capital Markets boosted their target price on shares of Amgen from $336.00 to $355.00 and gave the company an “outperform” rating in a research report on Friday. Finally, StockNews.com upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research note on Friday. Ten research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $305.05.

Amgen Trading Up 11.8 %

Shares of Amgen stock traded up $32.90 during trading on Friday, hitting $311.29. The company’s stock had a trading volume of 9,644,682 shares, compared to its average volume of 2,279,398. The stock has a market cap of $166.97 billion, a price-to-earnings ratio of 44.47, a price-to-earnings-growth ratio of 2.69 and a beta of 0.60. Amgen Inc. has a 52 week low of $211.71 and a 52 week high of $329.72. The stock has a 50-day moving average price of $274.95 and a two-hundred day moving average price of $281.50. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, May 2nd. The medical research company reported $3.96 EPS for the quarter, beating analysts’ consensus estimates of $3.76 by $0.20. Amgen had a return on equity of 145.62% and a net margin of 12.74%. The firm had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.45 billion. During the same quarter in the previous year, the company posted $3.98 EPS. The business’s revenue was up 22.0% on a year-over-year basis. Equities research analysts anticipate that Amgen Inc. will post 19.43 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be paid a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.89%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio is currently 128.57%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.